Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?

Detalles Bibliográficos
Autores principales: Macaluso, Fabio Salvatore, Orlando, Ambrogio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the AGA Institute 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214317/
https://www.ncbi.nlm.nih.gov/pubmed/32407807
http://dx.doi.org/10.1053/j.gastro.2020.05.026
_version_ 1783531942560399360
author Macaluso, Fabio Salvatore
Orlando, Ambrogio
author_facet Macaluso, Fabio Salvatore
Orlando, Ambrogio
author_sort Macaluso, Fabio Salvatore
collection PubMed
description
format Online
Article
Text
id pubmed-7214317
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher by the AGA Institute
record_format MEDLINE/PubMed
spelling pubmed-72143172020-05-12 Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19? Macaluso, Fabio Salvatore Orlando, Ambrogio Gastroenterology Correspondence by the AGA Institute 2021-04 2020-05-12 /pmc/articles/PMC7214317/ /pubmed/32407807 http://dx.doi.org/10.1053/j.gastro.2020.05.026 Text en © 2021 by the AGA Institute. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Macaluso, Fabio Salvatore
Orlando, Ambrogio
Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
title Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
title_full Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
title_fullStr Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
title_full_unstemmed Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
title_short Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
title_sort could patients with inflammatory bowel disease treated with immunomodulators or biologics be at lower risk for severe forms of covid-19?
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214317/
https://www.ncbi.nlm.nih.gov/pubmed/32407807
http://dx.doi.org/10.1053/j.gastro.2020.05.026
work_keys_str_mv AT macalusofabiosalvatore couldpatientswithinflammatoryboweldiseasetreatedwithimmunomodulatorsorbiologicsbeatlowerriskforsevereformsofcovid19
AT orlandoambrogio couldpatientswithinflammatoryboweldiseasetreatedwithimmunomodulatorsorbiologicsbeatlowerriskforsevereformsofcovid19

Ejemplares similares